-

AHF Rebukes Gilead Sciences As Prime Lawbreaking Drug Profiteer

While Bay Area drug company hosts shareholder meeting, AHF spotlights Gilead’s ongoing illegal tactics to maximize profit and greed

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the world’s largest HIV and AIDS healthcare provider, continued to expose Gilead Sciences’ despicable greed, as the company – maker of key HIV, hepatitis C, and COVID-19 drugs – hosted its virtual Annual General Meeting (AGM) Wednesday morning. Gilead keeps racking up exorbitant profits while restricting access to lifesaving medications.

In 2022, Gilead became one of 20 drug manufacturers to place unlawful restrictions on 340B contract pharmacy programs, a move that greatly reduces the number of prescriptions that nonprofit safety net care providers can fill for patients and clients.

In January of this year, AHF President Michael Weinstein wrote to Gilead CEO Daniel O’Day, asking Gilead to, “…return 340B drug discount savings entitled to nonprofit providers.” The letter (available at AHF’s www.gilead.org website) added the following:

“For ourselves, and on behalf of other impacted covered entities, we demand:

  1. Pricing equal to the lowest price paid by state ADAPs either individually or through negotiation with National Association of State and Territorial AIDS Directors.
  2. Restoration of the Advancing Access Medication Assistance Program terms that were in effect prior to January 1, 2022.
  3. Rollback of the 340B price increases that exceeded the rate of reimbursement increases over the past two years.
  4. Restoration of the sub-ceiling pricing for Descovy that was available to all covered entities prior to January 1, 2022.”

To date, AHF has received no reply from Gilead or Mr. O’Day.

About AHF

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 1.75 million individuals in 45 countries in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, follow us on Instagram and Twitter, and subscribe to our Ahfter Hours podcast.

Contacts

MEDIA CONTACTS:
Ged Kenslea, AHF, +1.323.791.5526 cell ged.kenslea@ahf.org
Jacki Schechner, AHF, +1.310.633.0547 cell jacki.schechner@ahf.org

AIDS Healthcare Foundation


Release Summary
AHF Rebukes Gilead Sciences As Prime Lawbreaking Drug Profiteer
Release Versions

Contacts

MEDIA CONTACTS:
Ged Kenslea, AHF, +1.323.791.5526 cell ged.kenslea@ahf.org
Jacki Schechner, AHF, +1.310.633.0547 cell jacki.schechner@ahf.org

More News From AIDS Healthcare Foundation

Washington State Saves a Critical Health Care Safety Net, Says AHF

OLYMPIA, Wash.--(BUSINESS WIRE)--Washington State Saves a Critical Health Care Safety Net, Says AHF...

Governor Signs Emergency Legislation Restoring HIV Medication Access for More Than 12,000 Floridians

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Governor Ron DeSantis has signed into law emergency legislation restoring access to life-saving HIV medications for more than 12,000 Floridians who lost coverage when the Florida Department of Health cut the state’s AIDS Drug Assistance Program on March 1. The legislation, which passed both chambers of the Florida Legislature unanimously, appropriates $30.9 million in emergency bridge funding through June 30, 2026, restores Florida’s AIDS Drug Assistance...

AHF Urges EU to Stop Blocking Health Equity

BRUSSELS--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) Europe will hold an advocacy action in Brussels on March 18 at 11:00 a.m. CET on Archimedes Street, followed by an in-person and virtual press conference at Press Club Brussels Europe titled “EU: Stop Blocking Health Equity,” urging European Commission (EC) decision-makers to support a legally binding Pathogen Access and Benefit-Sharing (PABS) Annex to the WHO Pandemic Agreement. Click here to access the Press conference Zoom link, and...
Back to Newsroom